早期抗逆转录病毒治疗中的可溶性CD14和IL-12p70预测治疗中断后的HIV负载设定点

Pien M van Paassen1,2, Anders C Boyd2,3, Alexander O Pasternak2,4

  • 1Laboratory for Viral Immune Pathogenesis, Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam.

AIDS (London, England)
|February 14, 2025
PubMed
概括

像sCD14和sCD163这样的可溶性生物标志物表明免疫激活,并在治疗中断后预测HIV病毒载量. 较低的IL-12p70水平与较高的病毒设定点相关,这表明HIV治愈策略的潜在生物标志物.